There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation Trust, London, UK. At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Prof. Devereux discusses the CLARITY trial (ISCRTN13751862), exploring a combination of ibrutinib and venetoclax, and the promise that this may in the future result in a curative therapy for certain patients.
Combination therapies in CLL: ibrutinib and venetoclax
